<DOC>
	<DOCNO>NCT00004002</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase I trial study effectiveness PS-341 treating patient advance solid tumor lymphoma respond previous treatment .</brief_summary>
	<brief_title>PS-341 Treating Patients With Advanced Solid Tumors Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine dose-limiting toxicity maximum tolerate dose PS-341 patient advance solid tumor lymphoma . II . Evaluate pharmacodynamics drug measure 20S proteasome inhibition patient . III . Assess change P53 P27 , possibly E2F-1 cyclin E , patient lymphoma response drug . IV . Evaluate objective tumor response drug patient . V. Evaluate relationship toxicity 20S proteasome inhibition blood accessible tumor tissue patient . VI . Evaluate response treatment drug patient measurable evaluable disease . OUTLINE : This dose-escalation , multicenter study . Patients receive PS-341 IV day 1 4 . Treatment repeat every 14 day least 2 course absence unacceptable toxicity disease progression . Patients stable respond disease may receive additional course discretion treat physician . Cohorts 3-6 patient receive escalate dos PS-341 maximum tolerate dose ( MTD ) determine . The MTD define dose 2 3 6 patient experience dose-limiting toxicity . Patients follow 4 week . PROJECTED ACCRUAL : A maximum 27 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced solid tumor lymphoma fail standard therapy standard option available No leukemia myeloma CNS lesion allow adequately treat surgery and/or radiotherapy symptomatically stable maintenance glucocorticoid require anticonvulsant least 3 month PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : SGOT great 2.5 time upper limit normal Bilirubin great 1.5 mg/dL Renal : Creatinine great 1.5 mg/dL Cardiovascular : No acute ischemia significant conduction abnormality ( i.e. , bifascicular block 2nd 3rd degree AV block ) Other : No serious medical psychiatric illness Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior bone marrow transplantation highdose chemotherapy radiolabeled monoclonal antibody therapy lymphoma patient Chemotherapy : At least 4 week since prior chemotherapy ( 6 week since nitrosoureas ) Endocrine therapy : See Disease Characteristics Radiotherapy : At least 4 week since prior radiotherapy Surgery : At least 2 week since prior major surgery Other : See Disease Characteristics No concurrent antiretroviral therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>